Company / Total Assets
Arrowhead Pharmaceuticals Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$1.4B
FY2025
5-year range
$691.9M / $1.4B
FY2021-FY2025
Trend
+21.5%
vs FY2024
Sector context
#59 of 214
Health Care
What the data says
At $1.4B, Arrowhead Pharmaceuticals's total assets ranks #59 of 214 in the Health Care sector. Total Assets has increased for 3 consecutive years, from $692M in FY2022 to $1.4B in FY2025.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of +21.5%.
Improved from $766M to $1.4B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- +21.5%
- 10-Year CAGR
- -
Sector benchmark
#59 of 214 in Health CareTop 28% of 214This company $1.4B Sector average $7.5B
▼
-81.5% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's total assets has grown for 3 consecutive years.
- 5-year CAGR of +21.5%, indicating consistent growth.
- In FY2025, total assets increased 21.5% year-over-year.
- Ranks #59 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | +21.5% |
| FY2024 | $1.1B | +48.9% |
| FY2023 | $765.6M | +10.6% |
| FY2022 | $691.9M | -2.6% |
| FY2021 | $710.1M | +35.9% |
| FY2020 | $522.5M | +49.4% |
| FY2019 | $349.8M | +213.5% |
| FY2018 | $111.6M | +7.3% |
| FY2017 | $104.0M | -18.8% |
| FY2016 | $128.2M | -3.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026